Insider Selling: Eli Lilly and Company (NYSE:LLY) EVP Sells $7,012,600.00 in Stock

Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anat Hakim also recently made the following trade(s):

• On Friday, August 7th, Anat Hakim sold 5,000 shares of Eli Lilly and Company stock. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,368.85 on Friday. The company has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 44.43, a PEG ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a 50-day simple moving average of $1,211.30 and a 200 day simple moving average of $1,099.50. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 EPS. Eli Lilly and Company’s quarterly revenue was up 38.6% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
• Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
• Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Integrity Financial Corp WA increased its position in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after buying an additional 8 shares in the last quarter. LCM Capital Management Inc boosted its holdings in Eli Lilly and Company by 3.3% in the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock worth $293,000 after acquiring an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV boosted its holdings in Eli Lilly and Company by 4.1% in the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock worth $235,000 after acquiring an additional 8 shares in the last quarter. Financial Network Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 5.6% in the third quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock worth $175,000 after acquiring an additional 8 shares in the last quarter. Finally, Eads & Heald Wealth Management grew its stake in Eli Lilly and Company by 0.5% in the third quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company’s stock valued at $1,700,000 after acquiring an additional 8 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on LLY shares. Royal Bank Of Canada boosted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research note on Friday, October 30th. Leerink Partners increased their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. Guggenheim lifted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Argus boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price for the company in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.